Navigation Links
CryoCor to Highlight Products at 13th Annual International Boston Atrial Fibrillation Symposium

Company to also Present at Stanford Group 13th Annual Healthcare Conference

SAN DIEGO, Jan. 15 /PRNewswire-FirstCall/ -- CryoCor, Inc. (Nasdaq: CRYO), a medical device company focused on the treatment of cardiac arrhythmias, announced today that it will showcase its Cardiac Cryoablation System and its next generation ablation catheter, Quantum, at the Boston Atrial Fibrillation Symposium, January 17-19, 2008. CryoCor's products will be located at Booth 801.

In August 2007, the FDA approved the Cryoablation System for the treatment of right atrial flutter and CryoCor completed enrollment of its pivotal clinical study of the System for the treatment of atrial fibrillation. The Company has completed animal studies with Quantum, which is designed to significantly reduce the required time for an atrial fibrillation catheter ablation. CryoCor expects to enter human trials with Quantum in the second quarter of 2008.

Ed Brennan, Ph.D., President and Chief Executive Officer of CryoCor, said, "The Boston AF Symposium is the premier industry event focused on the treatment of atrial fibrillation, and as such, offers a tremendous forum to showcase our products to potential users. We look forward to the opportunity to increase the knowledge of our Cryoablation System and the unique advantages our technology provides physicians."

The Company also announced that Edward F. Brennan, President and Chief Executive Officer, and Gregory J. Tibbitts, Chief Financial Officer, are scheduled to present at the Stanford Group 13th Annual Healthcare Conference in Washington, D.C. on Thursday, January 17, 2008 at 7:45 a.m. ET at The Four Seasons Hotel.

A live Web cast and recording of the presentation will be available online from the investor relations page of the Company's corporate Web site at The recording will remain available on CryoCor's Web site for at least 30 days following presentation.

About CryoCor

CryoCor is a medical technology company that has developed and manufactures a disposable catheter system based on its proprietary cryoablation technology for the minimally invasive treatment of cardiac arrhythmias. The Company's product, the CryoCor Cardiac Cryoablation System, or the Cryoablation System, is designed to treat cardiac arrhythmias through the use of cryoenergy, or extreme cold, to destroy targeted cardiac tissue. The Cryoablation System has been approved in Europe for the treatment of atrial fibrillation, and atrial flutter, the two most common and difficult to treat arrhythmias, since 2002. In the United States, CryoCor is conducting a pivotal trial to evaluate the safety and efficacy of the Cryoablation System for the treatment of atrial fibrillation and the Cryoablation System has been approved for the treatment of right atrial flutter. For more information please visit the Company's website at

Forward Looking Statements

The statements in this press release that are not descriptions of historical facts are forward-looking statements that are subject to risks and uncertainties. These include statements related to the advantages and benefits provided by the Company's technology and the timing for when the Company expects to enter human trials with Quantum. Such statements are only predictions and reflect CryoCor's expectations and assumptions as of the date of this press release based on currently available operating, financial, and competitive information. The actual events or results may differ materially from those projected in such forward-looking statements due to a number of factors, including risks involved with CryoCor's technology, its development and the Company's anticipated timetable for developing and evaluating its technology; risks involved with the diagnosis and treatment of atrial arrhythmias; risks associated with the Company's dependence on patents and proprietary rights; risks associated with the Company's protection and enforcement of its patents and proprietary rights; risks associated with the development or availability of competitive products or technologies; risks associated with the Company's ability to maintain and achieve milestones under collaborative agreements and the other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company expressly disclaims any intent or obligation to update any of these forward- looking statements.

CryoCor, Inc.

Gregory J. Tibbitts

Chief Financial Officer

(858) 909-2200

The Ruth Group

Nick Laudico / Zack Kubow (investors)

(646) 536-7030 / 7020

Jason Rando (media)

(646) 536-7025

SOURCE CryoCor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. CryoCor to Present at CIBC World Markets 18th Annual Healthcare Conference
2. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
3. Highlights of Economic and Business Growth in the Tampa Bay Region
4. Highlights of Economic and Business Growth in the Tampa Bay Region
5. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
6. Elekta Announces New Cancer Care Solutions and Highlights Personalized Efficiency at ASTRO 2007
7. Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference
8. Americas Heartland Launches Third Season Highlighting Contributions of American Farmers and Ranchers
9. Highlights of Economic and Business Growth in the Tampa Bay Region
10. Access Highlighted in Recent BusinessWeek Article
11. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
Post Your Comments:
(Date:10/13/2015)... PARK, N.J. and SAN DIEGO ... (BASF) and Mast Therapeutics, Inc. have agreed to collaborate ...  Currently, excipient-grade poloxamer 188 NF, marketed by BASF under ... used in a variety of pharmaceutical and biological applications, ... Poloxamer 188 is the starting material for Mast,s lead ...
(Date:10/13/2015)... , Oct. 13, 2015  Generex Biotechnology Corporation ( ... a non-binding Letter of Intent (LOI) with MediTemp Ltd. (MediTemp) ... a proprietary cooling technology designed to improve sperm quality in ... United States and three million men in ... 44 diagnosed as infertile.  For 42% of those men, the ...
(Date:10/13/2015)... ... , ... Proove Biosciences, a commercial and research leader ... Keck Medicine of the University of Southern California (USC) Pain Center to ... Research Clinical Objectives Linking Genotypic and Phenotypic Association with Pain Outcomes) is one ...
(Date:10/12/2015)... ... October 12, 2015 , ... Spirax Sarco, the leader in products ... CSM-C 600 compact clean steam generator . This unit is a skid ... of HTM2031, HTM2010, and EN285 standards. The CMS-C 600 generator can produce up ...
Breaking Biology Technology:
(Date:10/1/2015)... Oct. 1, 2015  Biometrics includes diverse set ... body characteristics, such as fingerprints, eye retinas, facial ... of biometrics technology has been constantly increasing in ... five years. In addition to the most prominent ... recognition, other means of biometric authentication are rapidly ...
(Date:9/29/2015)... , Sept. 29, 2015 News ... productivity while also saving energy , Minimized design ... Low Power Active Mode and embedded Fujitsu PalmSecure authentication ... Fujitsu today shows that good things come ... refreshed models to its enterprise desktop and mobile portfolio. ...
(Date:9/28/2015)... , September 28, 2015 ... expected to reach USD 12.03 billion by 2020, growing ... Technological advancements such as Backside Illumination (BSI) technique to ... over the forecast period.      (Logo: ... of the chip to reduce loss and, thus, reduce ...
Breaking Biology News(10 mins):